167 related articles for article (PubMed ID: 31805897)
1. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis.
Albrecht T; Rausch M; Rössler S; Albrecht M; Braun JD; Geissler V; Mehrabi A; Vogel MN; Pathil-Warth A; Mechtersheimer G; Renner M; Rupp C; Weiss KH; Busch E; Köhler B; Springfeld C; Schirmacher P; Goeppert B
BMC Cancer; 2019 Dec; 19(1):1191. PubMed ID: 31805897
[TBL] [Abstract][Full Text] [Related]
2. HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma.
Albrecht T; Rausch M; Roessler S; Geissler V; Albrecht M; Halske C; Seifert C; Renner M; Singer S; Mehrabi A; Vogel MN; Pathil-Warth A; Busch E; Köhler B; Rupp C; Weiss KH; Springfeld C; Röcken C; Schirmacher P; Goeppert B
Virchows Arch; 2020 Jun; 476(6):871-880. PubMed ID: 31838585
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham RP; Barr Fritcher EG; Pestova E; Schulz J; Sitailo LA; Vasmatzis G; Murphy SJ; McWilliams RR; Hart SN; Halling KC; Roberts LR; Gores GJ; Couch FJ; Zhang L; Borad MJ; Kipp BR
Hum Pathol; 2014 Aug; 45(8):1630-8. PubMed ID: 24837095
[TBL] [Abstract][Full Text] [Related]
4. Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma.
Jung MJ; Woo CG; Lee S; Chin S; Kim HK; Kwak JJ; Koh ES; Lee B; Jang KT; Moon A
Pathology; 2017 Oct; 49(6):582-588. PubMed ID: 28843919
[TBL] [Abstract][Full Text] [Related]
5. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
6. Target molecular treatment markers in Intrahepatic Cholangiocarcinoma based on Chinese population.
Pu X; Zhu L; Li F; Zheng J; Wu H; Fu Y; Chen J; Qi L
Pathol Res Pract; 2020 Sep; 216(9):153116. PubMed ID: 32825971
[TBL] [Abstract][Full Text] [Related]
7. Low-level clonal FGFR2 amplification defines a unique molecular subtype of intrahepatic cholangiocarcinoma in a Chinese population.
Pu XH; Ye Q; Yang J; Wu HY; Ding XW; Shi J; Mao L; Fan XS; Chen J; Qiu YD; Huang Q
Hum Pathol; 2018 Jun; 76():100-109. PubMed ID: 29514108
[TBL] [Abstract][Full Text] [Related]
8. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
9. Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.
Sirica AE
World J Gastroenterol; 2008 Dec; 14(46):7033-58. PubMed ID: 19084911
[TBL] [Abstract][Full Text] [Related]
10. C-MET in intrahepatic cholangiocarcinoma: High-Frequency amplification predicts protein expression and a unique molecular subtype.
Pu XH; Yue S; Wu HY; Yang J; Fan XS; Fu Y; Ye Q; Chen J
Pathol Res Pract; 2020 Apr; 216(4):152857. PubMed ID: 32089411
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and HER-2/neu status by immunohistochemistry and fluorescence in situ hybridization in adenocarcinomas of the biliary tree and gallbladder.
Shafizadeh N; Grenert JP; Sahai V; Kakar S
Hum Pathol; 2010 Apr; 41(4):485-92. PubMed ID: 20040392
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of C-NEU and C-MET during rat liver cholangiocarcinogenesis: A link between biliary intestinal metaplasia and mucin-producing cholangiocarcinoma.
Radaeva S; Ferreira-Gonzalez A; Sirica AE
Hepatology; 1999 May; 29(5):1453-62. PubMed ID: 10216129
[TBL] [Abstract][Full Text] [Related]
13. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
Galdy S; Lamarca A; McNamara MG; Hubner RA; Cella CA; Fazio N; Valle JW
Cancer Metastasis Rev; 2017 Mar; 36(1):141-157. PubMed ID: 27981460
[TBL] [Abstract][Full Text] [Related]
14. EGFR gene amplification is relatively common and associates with outcome in intestinal adenocarcinoma of the stomach, gastro-oesophageal junction and distal oesophagus.
Birkman EM; Ålgars A; Lintunen M; Ristamäki R; Sundström J; Carpén O
BMC Cancer; 2016 Jul; 16():406. PubMed ID: 27387915
[TBL] [Abstract][Full Text] [Related]
15. HER2/neu (ERBB2) expression and gene amplification correlates with better survival in esophageal adenocarcinoma.
Plum PS; Gebauer F; Krämer M; Alakus H; Berlth F; Chon SH; Schiffmann L; Zander T; Büttner R; Hölscher AH; Bruns CJ; Quaas A; Loeser H
BMC Cancer; 2019 Jan; 19(1):38. PubMed ID: 30621632
[TBL] [Abstract][Full Text] [Related]
16. Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
Gomez-Martin C; Plaza JC; Pazo-Cid R; Salud A; Pons F; Fonseca P; Leon A; Alsina M; Visa L; Rivera F; Galan MC; Del Valle E; Vilardell F; Iglesias M; Fernandez S; Landolfi S; Cuatrecasas M; Mayorga M; Jose Paulés M; Sanz-Moncasi P; Montagut C; Garralda E; Rojo F; Hidalgo M; Lopez-Rios F
J Clin Oncol; 2013 Dec; 31(35):4445-52. PubMed ID: 24127447
[TBL] [Abstract][Full Text] [Related]
17. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.
Liu TT; You HL; Weng SW; Wei YC; Eng HL; Huang WT
PLoS One; 2015; 10(12):e0145388. PubMed ID: 26684807
[TBL] [Abstract][Full Text] [Related]
18. Bile duct expression of pancreatic and duodenal homeobox 1 in perihilar cholangiocarcinogenesis.
Igarashi S; Matsubara T; Harada K; Ikeda H; Sato Y; Sasaki M; Matsui O; Nakanuma Y
Histopathology; 2012 Aug; 61(2):266-76. PubMed ID: 22594685
[TBL] [Abstract][Full Text] [Related]
19. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease.
Tanaka R; Sasajima Y; Tsuda H; Namikawa K; Tsutsumida A; Otsuka F; Yamazaki N
Br J Dermatol; 2013 Jun; 168(6):1259-66. PubMed ID: 23360223
[TBL] [Abstract][Full Text] [Related]
20. HER2/neu-directed therapy for biliary tract cancer.
Javle M; Churi C; Kang HC; Shroff R; Janku F; Surapaneni R; Zuo M; Barrera C; Alshamsi H; Krishnan S; Mishra L; Wolff RA; Kaseb AO; Thomas MB; Siegel AB
J Hematol Oncol; 2015 May; 8():58. PubMed ID: 26022204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
